文献速递血液净化与透析

维持性血液透析患者中高剂量与标准剂量流感疫苗的比较效果

Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccine Among Patients Receiving Maintenance Hemodialysis.
PubMed 文献 · Am J Kidney Dis · 2019-08-01

本研究基于美国肾脏数据系统,纳入2010-2011至2014-2015流感季的507,552名成人中心血液透析患者,比较标准剂量与高剂量流感疫苗的效果。在225,215个流感患者-季中,97.4%接种标准剂量,2.6%接种高剂量;两组在全因死亡、流感或肺炎住院及流感样疾病的风险差异均无统计学意义。结论提示高剂量疫苗未提供额外保护,应考虑其额外成本和副作用。

要点

  • 高剂量与标准剂量流感疫苗在全因死亡、流感相关住院和流感样疾病上风险相似。
  • 亚组分析(年龄、透析龄、接种月份、疫苗效价等)结果一致。
  • 为血液透析患者选择高剂量疫苗时需权衡额外成本和副作用。

核心结论

  • 高剂量流感疫苗在维持性血液透析成人中未较标准剂量疫苗提供额外保护。

研究设计与样本

  • 基于美国肾脏数据系统的队列研究,纳入507,552名成人中心维持性血液透析患者。
  • 分析单位为流感患者-季,覆盖2010-2011至2014-2015流感季。
  • 采用倾向评分加权Kaplan-Meier函数估计风险差异和风险比,非死亡结局使用竞争风险方法。

主要发现

  • 在≥65岁成人225,215个流感患者-季中,97.4%接种标准剂量,2.6%接种高剂量。
  • 全因死亡风险差异-0.08%(95%CI -0.85%至0.80%)。
  • 流感或肺炎住院风险差异0.15%(95%CI -0.69%至0.93%)。
  • 流感样疾病风险差异0.00%(95%CI -1.50%至1.08%)。
  • 亚组分析(年龄<65岁、流感季、年龄组、透析龄、接种月份、疫苗效价)结果相似。

临床怎么用

  • 对于维持性血液透析成人,高剂量流感疫苗未显示优于标准剂量疫苗的额外保护。
  • 选择高剂量疫苗时应考虑其额外成本和副作用。

局限性

  • 存在残余混杂。
  • 结局可能存在错误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Studies of patients on maintenance dialysis therapy suggest that standard-dose influenza vaccine (SDV) may not prevent influenza-related outcomes. Little is known about the comparative effectiveness of SDV versus high-dose influenza vaccine (HDV) in this population. STUDY DESIGN: Cohort study using data from the US Renal Data System. SETTING & PARTICIPANTS: 507,552 adults undergoing in-center maintenance hemodialysis between the 2010 to 2011 and 2014 to 2015 influenza seasons. EXPOSURES: SDV and HDV. OUTCOMES: All-cause mortality, hospitalization due to influenza or pneumonia, and influenza-like illness during the influenza season. ANALYTIC APPROACH: Patients were eligible for inclusion in multiple yearly cohorts; thus, our unit of analysis was the influenza patient-season. To examine the relationship between vaccine dose and effectiveness outcomes, we estimated risk differences and risk ratios using propensity score weighting of Kaplan-Meier functions, accounting for a wide range of patient- and facility-level characteristics. For nonmortality outcomes, we used competing-risk methods to account for the high mortality rate in the dialysis population. RESULTS: Within 225,215 influenza patient-seasons among adults 65 years and older, 97.4% received SDV and 2.6% received HDV. We observed similar risk estimates for HDV and SDV recipients for mortality (risk difference, -0.08%; 95% CI, -0.85% to 0.80%), hospitalization due to influenza or pneumonia (risk difference, 0.15%; 95% CI, -0.69% to 0.93%), and influenza-like illness (risk difference, 0.00%; 95% CI, -1.50% to 1.08%). Our findings were similar among adults younger than 65 years, as well as within other subgroups defined by influenza season, age group, dialysis vintage, month of influenza vaccination, and vaccine valence. LIMITATIONS: Residual confounding and outcome misclassification. CONCLUSIONS: The HDV does not appear to provide additional protection beyond the SDV against all-cause mortality or influenza-related outcomes for adults undergoing hemodialysis. The additional cost and side effects associated with HDV should be considered when offering this vaccine. Future studies of HDV and other influenza vaccine strategies are warranted.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Butler AM, Layton JB, Dharnidharka VR, et al. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccine Among Patients Receiving Maintenance Hemodialysis. Am J Kidney Dis. 2019. PMID: 31378646. doi:10.1053/j.ajkd.2019.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。